173 related articles for article (PubMed ID: 28393315)
21. Molecular mechanisms of breast cancer metastasis by gene expression profile analysis.
Zheng T; Wang A; Hu D; Wang Y
Mol Med Rep; 2017 Oct; 16(4):4671-4677. PubMed ID: 28791367
[TBL] [Abstract][Full Text] [Related]
22. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ
Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022
[TBL] [Abstract][Full Text] [Related]
23. PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells.
Jegg AM; Ward TM; Iorns E; Hoe N; Zhou J; Liu X; Singh S; Landgraf R; Pegram MD
Breast Cancer Res Treat; 2012 Dec; 136(3):683-92. PubMed ID: 23089982
[TBL] [Abstract][Full Text] [Related]
24. Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer.
Fabi A; Merola R; Ferretti G; Di Benedetto A; Antoniani B; Ercolani C; Nisticò C; Papaldo P; Ciccarese M; Sperduti I; Vici P; Marino M; Gori S; Botti C; Malaguti P; Cognetti F; Mottolese M
Expert Opin Pharmacother; 2013 Apr; 14(6):699-706. PubMed ID: 23472669
[TBL] [Abstract][Full Text] [Related]
25. Investigating the therapeutic potential and mechanism of curcumin in breast cancer based on RNA sequencing and bioinformatics analysis.
Wang R; Li J; Zhao Y; Li Y; Yin L
Breast Cancer; 2018 Mar; 25(2):206-212. PubMed ID: 29139094
[TBL] [Abstract][Full Text] [Related]
26. Identification of key pathways and genes in colorectal cancer using bioinformatics analysis.
Liang B; Li C; Zhao J
Med Oncol; 2016 Oct; 33(10):111. PubMed ID: 27581154
[TBL] [Abstract][Full Text] [Related]
27. Identification of genes and pathways associated with MDR in MCF-7/MDR breast cancer cells by RNA-seq analysis.
Yang M; Li H; Li Y; Ruan Y; Quan C
Mol Med Rep; 2018 May; 17(5):6211-6226. PubMed ID: 29512753
[TBL] [Abstract][Full Text] [Related]
28. Identification and characterization of biomarkers and their functions for docetaxel-resistant prostate cancer cells.
Deng L; Gu X; Zeng T; Xu F; Dong Z; Liu C; Chao H
Oncol Lett; 2019 Sep; 18(3):3236-3248. PubMed ID: 31452801
[TBL] [Abstract][Full Text] [Related]
29. Identification of key genes involved in HER2-positive breast cancer.
Zhong BL; Bian LJ; Wang GM; Zhou YF; Chen YY; Peng F
Eur Rev Med Pharmacol Sci; 2016; 20(4):664-72. PubMed ID: 26957268
[TBL] [Abstract][Full Text] [Related]
30. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
31. Identification of Key Genes and Pathways in Pancreatic Cancer Gene Expression Profile by Integrative Analysis.
Lu W; Li N; Liao F
Genes (Basel); 2019 Aug; 10(8):. PubMed ID: 31412643
[TBL] [Abstract][Full Text] [Related]
32. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K
Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301
[TBL] [Abstract][Full Text] [Related]
33. Transcriptomic Profiling Identifies Differentially Expressed Genes in Palbociclib-Resistant ER+ MCF7 Breast Cancer Cells.
Lanceta L; O'Neill C; Lypova N; Li X; Rouchka E; Waigel S; Gomez-Gutierrez JG; Chesney J; Imbert-Fernandez Y
Genes (Basel); 2020 Apr; 11(4):. PubMed ID: 32344635
[TBL] [Abstract][Full Text] [Related]
34. Prediction of signaling cross-talks contributing to acquired drug resistance in breast cancer cells by Bayesian statistical modeling.
Azad AK; Lawen A; Keith JM
BMC Syst Biol; 2015 Jan; 9():2. PubMed ID: 25599599
[TBL] [Abstract][Full Text] [Related]
35. Protein-protein interaction network and significant gene analysis of osteoporosis.
Wu XM; Ma X; Tang C; Xie KN; Liu J; Guo W; Yan YL; Shen GH; Luo EP
Genet Mol Res; 2013 Oct; 12(4):4751-9. PubMed ID: 24222250
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms of lapatinib resistance in HER2-driven breast cancer.
D'Amato V; Raimondo L; Formisano L; Giuliano M; De Placido S; Rosa R; Bianco R
Cancer Treat Rev; 2015 Dec; 41(10):877-83. PubMed ID: 26276735
[TBL] [Abstract][Full Text] [Related]
37. Detection and screening of small molecule agents for overcoming Sorafenib resistance of hepatocellular carcinoma: a bioinformatics study.
Lv J; Zhu B; Zhang L; Xie Q; Zhuo W
Int J Clin Exp Med; 2015; 8(2):2317-25. PubMed ID: 25932168
[TBL] [Abstract][Full Text] [Related]
38. RON confers lapatinib resistance in HER2-positive breast cancer cells.
Wang Q; Quan H; Zhao J; Xie C; Wang L; Lou L
Cancer Lett; 2013 Oct; 340(1):43-50. PubMed ID: 23811285
[TBL] [Abstract][Full Text] [Related]
39. Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.
Chefrour M; Milano G; Formento P; Giacometti S; Denden A; Renée N; Iliadis A; Fischel JL; Ciccolini J
Fundam Clin Pharmacol; 2012 Aug; 26(4):530-7. PubMed ID: 21623901
[TBL] [Abstract][Full Text] [Related]
40. Identification of key microRNAs and genes in preeclampsia by bioinformatics analysis.
Luo S; Cao N; Tang Y; Gu W
PLoS One; 2017; 12(6):e0178549. PubMed ID: 28594854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
